Delineate
Agents for Accelerated Clinical Trial Design
What they do
Clinical trial design and progression is slow and labor-intensive, delaying drug development and increasing costs for pharma companies.
AI agents that process existing clinical trial research into specialized datasets to accelerate and improve clinical trial design and phase advancement.
Large pharmaceutical companies and clinical trial teams designing and running drug trials.
Founders
Co-founder at Delineate. Previously she was an MIT PhD Candidate in Biological Engineering and worked at Pfizer and AstraZeneca where she focused on applying AI to modeling and simulation for drug development optimization.
Co-Founder and CTO of Delineate. Masters thesis in Robotics/AI with 2 research publications. Former technical project manager for high impact digital transformation projects within Skunkworks (Advanced Development) division at Lockheed Martin.
Company timeline
- Founded2024
- YC batchWinter 2025
- StatusActive
- Team size20 people
- LocationBoston, MA, USA; Remote
